PE20210044A1 - Compuestos para el tratamiento de trastornos dependientes de cinasas - Google Patents

Compuestos para el tratamiento de trastornos dependientes de cinasas

Info

Publication number
PE20210044A1
PE20210044A1 PE2020001120A PE2020001120A PE20210044A1 PE 20210044 A1 PE20210044 A1 PE 20210044A1 PE 2020001120 A PE2020001120 A PE 2020001120A PE 2020001120 A PE2020001120 A PE 2020001120A PE 20210044 A1 PE20210044 A1 PE 20210044A1
Authority
PE
Peru
Prior art keywords
compounds
treatment
kine
dependent disorders
formula
Prior art date
Application number
PE2020001120A
Other languages
English (en)
Inventor
Lynne Canne Bannen
Minna Bui
Faming Jiang
Yong Wang
Wei Xu
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of PE20210044A1 publication Critical patent/PE20210044A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se describen en la presente compuestos de la Formula I'. Los compuestos de la Formula I' inhiben, regulan y/o modulan el receptor de cinasa, particularmente las vias de transduccion de senales de Axl y Mer relacionadas con los cambios en las actividades celulares mencionados anteriormente, las composiciones que contienen estos compuestos y los metodos para usarlos para el tratamiento de enfermedades y afecciones dependientes de cinasas. La presente invencion tambien proporciona metodos para la confeccion de compuestos mencionados anteriormente, y composiciones que contienen estos compuestos.
PE2020001120A 2018-01-26 2019-01-25 Compuestos para el tratamiento de trastornos dependientes de cinasas PE20210044A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862622629P 2018-01-26 2018-01-26
US201862622626P 2018-01-26 2018-01-26
PCT/US2019/015289 WO2019148036A1 (en) 2018-01-26 2019-01-25 Compounds for the treatment of kinase-dependent disorders

Publications (1)

Publication Number Publication Date
PE20210044A1 true PE20210044A1 (es) 2021-01-08

Family

ID=65409542

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001120A PE20210044A1 (es) 2018-01-26 2019-01-25 Compuestos para el tratamiento de trastornos dependientes de cinasas

Country Status (17)

Country Link
US (2) US11708367B2 (es)
EP (1) EP3743068A1 (es)
JP (2) JP7307733B2 (es)
KR (1) KR20200124678A (es)
AU (1) AU2019212719A1 (es)
BR (1) BR112020015199A2 (es)
CA (1) CA3088127A1 (es)
CL (1) CL2020001930A1 (es)
CO (1) CO2020010467A2 (es)
CR (1) CR20200355A (es)
IL (2) IL302626A (es)
MA (1) MA51672A (es)
MX (2) MX2020007759A (es)
PE (1) PE20210044A1 (es)
PH (1) PH12020551059A1 (es)
SG (1) SG11202006945PA (es)
WO (1) WO2019148036A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7307733B2 (ja) * 2018-01-26 2023-07-12 エグゼリクシス， インコーポレイテッド キナーゼ依存的障害を処置するための化合物
MA51673A (fr) * 2018-01-26 2020-12-02 Exelixis Inc Composés destinés au traitement de troubles dépendant de la kinase
MA51679A (fr) 2018-01-26 2020-12-02 Exelixis Inc Composés destinés au traitement de troubles dépendant de la kinase
CN112457308B (zh) 2019-09-09 2024-01-02 上海长森药业有限公司 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用
WO2021180006A1 (zh) * 2020-03-10 2021-09-16 南京明德新药研发有限公司 乙烯基取代吡啶类化合物
GB202004960D0 (en) * 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
ES2332984T3 (es) 1995-03-30 2010-02-16 Pfizer Products Inc. Derivados de quinazolinas.
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
SI0892789T2 (sl) 1996-04-12 2010-03-31 Warner Lambert Co Ireverzibilni inhibitorji tirozin kinaz
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
JP4679517B2 (ja) 2003-07-23 2011-04-27 エグゼリクシス， インコーポレイテッド 薬剤としてのアゼピン誘導体
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
CA2604238C (en) 2005-04-15 2015-07-07 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
CA3151350A1 (en) 2005-05-09 2006-11-16 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
RU2008139599A (ru) 2006-03-07 2010-04-20 Эррэй Биофарма Инк. (Us) Гетеробициклические производные пиразола и способы их применения
JP5734193B2 (ja) 2008-10-14 2015-06-17 クイ ニング 化合物及び使用方法
EP2213686A1 (en) 2009-01-28 2010-08-04 Externautics S.p.A. Tumor markers and methods of use thereof
EP2214019A1 (en) 2009-01-28 2010-08-04 Externautics S.p.A. Tumor markers and methods of use thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2493917B8 (en) 2009-10-26 2020-03-04 Externautics S.P.A. Breast tumor markers and methods of use thereof
WO2011051280A1 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Ovary tumor markers and methods of use thereof
EP2494351B1 (en) 2009-10-26 2016-06-08 Externautics S.p.A. Colon and rectal tumor markers and methods of use thereof
WO2011051278A1 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Lung tumor markers and methods of use thereof
US8921058B2 (en) 2009-10-26 2014-12-30 Externautics Spa Prostate tumor markers and methods of use thereof
EP2383578A1 (en) 2010-04-30 2011-11-02 Externautics S.p.A. Tumor marker and methods of use thereof
AU2011278832B2 (en) 2010-07-14 2014-03-13 Betta Pharmaceuticals Co., Ltd Novel fused heterocyclic derivatives useful as c-Met tyrosine kinase inhibitors
US8664244B2 (en) 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
CN102093421B (zh) 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
AU2013326901B2 (en) 2012-10-04 2018-05-31 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-PD-L1 antibodies and methods of use
KR102243062B1 (ko) 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
WO2014198919A2 (en) 2013-06-14 2014-12-18 Externautics S.P.A. Tumor marker, monoclonal antibodies and methods of use thereof
AU2014346852A1 (en) 2013-11-05 2016-06-16 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
KR102474701B1 (ko) 2014-04-25 2022-12-05 엑셀리시스, 인코포레이티드 폐 선암종을 치료하는 방법
CN104817497B (zh) 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
CN106279147A (zh) 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
US20180009758A1 (en) 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
CN105797123A (zh) 2016-05-18 2016-07-27 王超 一种治疗***不育的中药组合物
CN106400155A (zh) 2016-08-31 2017-02-15 飞佛特种纺织品（宁波）有限公司 一种防老化阳光面料
CN110437145A (zh) 2016-09-13 2019-11-12 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
US11358949B2 (en) 2017-12-20 2022-06-14 Angex Pharmaceutical, Inc. Carbamate and urea compounds as multikinase inhibitors
JP7307733B2 (ja) * 2018-01-26 2023-07-12 エグゼリクシス， インコーポレイテッド キナーゼ依存的障害を処置するための化合物

Also Published As

Publication number Publication date
AU2019212719A1 (en) 2020-08-20
CL2020001930A1 (es) 2020-12-11
KR20200124678A (ko) 2020-11-03
IL302626A (en) 2023-07-01
US11708367B2 (en) 2023-07-25
MX2020007759A (es) 2020-09-24
MA51672A (fr) 2020-12-02
JP2021511359A (ja) 2021-05-06
SG11202006945PA (en) 2020-08-28
US20230374024A1 (en) 2023-11-23
CO2020010467A2 (es) 2020-10-30
EP3743068A1 (en) 2020-12-02
CR20200355A (es) 2021-02-22
IL276028A (en) 2020-08-31
MX2022014351A (es) 2022-12-13
CA3088127A1 (en) 2019-08-01
PH12020551059A1 (en) 2021-05-31
JP2023082042A (ja) 2023-06-13
JP7307733B2 (ja) 2023-07-12
BR112020015199A2 (pt) 2021-05-04
US20210040099A1 (en) 2021-02-11
CN112312909A (zh) 2021-02-02
WO2019148036A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
CO2020010465A2 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas
PE20210044A1 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas
CL2019001988A1 (es) Compuestos químicos como inhibidores de actividad interleuquina-2.
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CL2020002511A1 (es) Compuestos heterocíclicos como inmunomoduladores.
MX2020004534A (es) Moduladores de la vía integrada del estrés.
CO2021005987A2 (es) Compuestos de anillo fusionado
CO2022002759A2 (es) Antagonistas de hpk1 y sus usos
CU20200046A7 (es) Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47
CU20180006A7 (es) Compuestos de indazaol y azaindazol como inhibidores de irak-4
MX2020004538A (es) Moduladores de la vía de estrés integrada.
BR112018067775A2 (pt) inibidores de mcl-1 indol substituído
CL2013002690A1 (es) Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer.
CU20140118A7 (es) Compuestos de indol e indazol que activan la ampk
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
UY31027A1 (es) Derivados de tetrahidroindol y tetrahidroindazol
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
DOP2023000145A (es) Inhibidores de cdk2 y métodos de uso de los mismos
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
CA3139156A1 (en) Compounds for the treatment of kinase-dependent disorders
CO2022011258A2 (es) Pirazolo-pirimidinas sustituidas y usos de las mismas
CL2018001631A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
CL2021000282A1 (es) Inhibidores de ckd8/19
ECSP067096A (es) Metabolitos de indolilalquilamina como ligandos 5-hidroxitriptamina-6
EA202092446A1 (ru) ТИАЗОЛ- ИЛИ ТИАДИАЗОЛЗАМЕЩЕННЫЕ АРИЛЬНЫЕ И ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ Vps34